Premium
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
Author(s) -
BachleitnerHofmann T.,
Gisslinger B.,
Grumbeck E.,
Gisslinger H.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02608.x
Subject(s) - arsenic trioxide , ascorbic acid , myeloid leukaemia , acute promyelocytic leukemia , myeloid , medicine , apoptosis , dehydroascorbic acid , chemistry , retinoic acid , biochemistry , food science , gene
Arsenic trioxide (As 2 O 3 ) induces remission in a high proportion of patients with acute promyelocytic leukaemia (APL) via induction of apoptosis. Preliminary reports suggest that the apoptotic effect of As 2 O 3 is not specific for APL but can also be observed in non‐APL acute myeloid leukaemia (AML) cells, although these are less sensitive than APL cells. Ascorbic acid has recently been demonstrated to enhance the apoptotic effect of As 2 O 3 . We have therefore evaluated combined As 2 O 3 /ascorbic acid treatment in various clinical samples of AML. Our results indicate a significant synergistic effect of As 2 O 3 and ascorbic acid, suggesting a possible future role of As 2 O 3 /ascorbic acid combination therapy in patients with AML.